Likelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Endometrial Cancer
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Endometrial Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Cadonilimab in Endometrial Cancer Drug Details:
Cardinalizumab (Ketanil) is a bi-specific antibody acts as programmed death 1 protein (PD-1) antagonist and CTLA4 antagonist. It is formulated as solution for inravenous route of administration. Ketanil is indicated for the treatment of recurrent or metastatic cervical cancer (R/M CC) who had failed previous platinum-containing chemotherapy.Cadonilimab is under development for the treatment of recurrent head and neck squamous cell carcinoma (including primary sites such as oral cavity, oropharynx, larynx or hypopharynx cancer), advanced or metastatic squamous or metastatic non-squamous non-small cell lung carcinoma, malignant pleural mesothelioma, fallopian tube cancer and primary peritoneal cancer, vaginal cancer, signet ring cell squamous cell carcinoma, adenocarcinoma of the gastroesophageal junction, adenosquamous cell carcinoma and solid tumors including cervical cancer, gastric cancer, hepatocellular carcinoma, esophageal squamous-cell carcinoma, locally recurrent and oligometastatic endometrial carcinoma, epithelial ovarian cancer, colorectal cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, transitional cell cancer (urothelial cell cancer), esophageal squamous cell carcinoma, triple-negative breast cancer, melanoma, mesothelioma, large-cell neuroendocrine carcinoma, colorectal cancer, non-small cell lung cancer small-cell lung cancer, melanoma, nasopharyngeal cancer, stomach cancer, urothelial carcinoma, metastatic soft tissue sarcoma, mainly including undifferentiated pleomorphic sarcoma/malignant fiber histiocytoma, alveolar soft part sarcoma, dedifferentiated liposarcoma, fibrosarcoma, leiomyosarcoma, angiosarcoma, synovial sarcoma, pancreatic ductal adenocarcinoma (PDAC), metastatic pancreatic cancer, vulvar cancer and metastatic clear cell renal cell carcinoma (ccRCC). It is administered by intravenous route. The drug candidate is a bi-specific monoclonal antibody. It acts by targeting programmed cell death protein 1 (PD-1) and Cytotoxic T Lymphocyte Protein 4 (CTLA4).It was also under development for the treatment of peripheral T cell lymphoma.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Cadonilimab LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports